Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 12.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,785 shares of the pharmaceutical company’s stock after acquiring an additional 199 shares during the period. Fidelis Capital Partners LLC’s holdings in Vertex Pharmaceuticals were worth $726,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. OFI Invest Asset Management acquired a new position in Vertex Pharmaceuticals during the 3rd quarter valued at about $25,000. Arlington Trust Co LLC boosted its position in shares of Vertex Pharmaceuticals by 97.1% during the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 33 shares in the last quarter. Compass Wealth Management LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $29,000. Fortitude Family Office LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $30,000. Finally, Baystate Wealth Management LLC boosted its position in shares of Vertex Pharmaceuticals by 49.0% during the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 25 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Activity

In other news, COO Stuart A. Arbuckle sold 4,295 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the sale, the chief operating officer now owns 75,718 shares of the company’s stock, valued at approximately $31,819,732.32. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the sale, the executive vice president now owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Stuart A. Arbuckle sold 4,295 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,804,930.80. Following the sale, the chief operating officer now directly owns 75,718 shares of the company’s stock, valued at approximately $31,819,732.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 12,381 shares of company stock valued at $5,203,249. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Stock Up 0.5 %

NASDAQ:VRTX traded up $2.10 during trading hours on Friday, reaching $395.58. 237,185 shares of the stock were exchanged, compared to its average volume of 1,231,383. Vertex Pharmaceuticals Incorporated has a twelve month low of $316.43 and a twelve month high of $448.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78. The firm has a 50 day moving average of $414.17 and a 200 day moving average of $396.74. The stock has a market cap of $102.24 billion, a PE ratio of 28.33, a PEG ratio of 1.85 and a beta of 0.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating the consensus estimate of $3.85 by $0.35. The company had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same quarter in the prior year, the firm posted $3.33 EPS. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on VRTX. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 6th. UBS Group reduced their price objective on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a research report on Wednesday. Maxim Group lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Oppenheimer reiterated an “outperform” rating and issued a $500.00 target price on shares of Vertex Pharmaceuticals in a report on Monday. Finally, Truist Financial raised their target price on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Three analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $429.45.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.